Biodexa Pharmaceuticals (BDRX) Income towards Parent Company (2013 - 2025)
Biodexa Pharmaceuticals (BDRX) reported Income towards Parent Company of -$5.1 million for Q2 2025, down 19.59% sequentially from -$4.2 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Income towards Parent Company (2013 - 2025) Analysis & Trends
Biodexa Pharmaceuticals (BDRX) has 13 years of Income towards Parent Company data on file, last reported at -$5.1 million in Q2 2025.
- For the quarter ending Q2 2025, Income towards Parent Company changed N/A year-over-year to -$5.1 million; the trailing twelve-month figure through Dec 2025 stood at -$9.3 million (up 48.21% YoY), and the FY2025 full-year result was -$8.7 million, down 104.77% from the prior year.
- Income towards Parent Company retreated to -$5.1 million in Q2 2025, from -$4.2 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$3.6 million in Q4 2022 to a low of -$9.3 million in Q4 2023.
- A 5-year average of -$4.9 million and a median of -$4.3 million in 2021 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company jumped 81.52% in 2021 and tumbled 158.75% in 2023, its largest moves.
- Tracing BDRX's Income towards Parent Company over 5 years: stood at -$4.3 million in 2021, then gained by 15.55% to -$3.6 million in 2022, then plunged by 158.75% to -$9.3 million in 2023, then surged by 54.3% to -$4.2 million in 2024, then decreased by 19.59% to -$5.1 million in 2025.
- Business Quant data shows BDRX's Income towards Parent Company at -$5.1 million in Q2 2025, -$4.2 million in Q4 2024, and -$9.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,935.05 Bn | 1,934.98 Bn | - |
| 3 | Akari Therapeutics | 1,021.31 Bn | 1,021.31 Bn | - |
| 4 | BeOne Medicines | 467.89 Bn | 463.10 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.19 Bn | 61.44 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.46 Bn | 63.46 Bn | - |
| 8 | Argenx Se | 55.64 Bn | 50.45 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Biodexa Pharmaceuticals | 18.76 Bn | 18.75 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.08 Mn |
| Dec 31, 2024 | -4.25 Mn |
| Dec 31, 2023 | -9.29 Mn |
| Jun 30, 2023 | -4.46 Mn |
| Dec 31, 2022 | -3.59 Mn |
| Sep 14, 2022 | -3.79 Mn |
| Dec 31, 2021 | -4.25 Mn |
| Sep 17, 2021 | -4.38 Mn |
| Dec 31, 2020 | -23.00 Mn |
| Sep 10, 2020 | -23.04 Mn |
| Dec 31, 2019 | -1.22 Mn |
| Dec 31, 2018 | -6.00 Mn |
| Dec 31, 2017 | -5.79 Mn |
| Dec 31, 2016 | -15.37 Mn |
| Dec 31, 2015 | -15.33 Mn |
| Dec 31, 2014 | -13.98 Mn |
| Dec 31, 2013 | -6.61 Mn |